이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

SK bioscience realigns structure for responsible management

Collected: 2023.12.08

Distributed: 2023.12.09

Source: Go Direct

[Photo by Yonhap]

SK bioscience is embarking on an organizational realignment centered around the transition to a divisional responsibility management system, with a key focus on enhancing quality via a new Quality Excellence (QE) unit.

The company announced its plans to implement a 2024 organizational change effective December 13 on Thursday. The existing structure will be reorganized into six departments: Business Development (BD), Bio Research, Development, L House, Quality, and Management Support, with each department undergoing a shift towards a responsibility management system as well as aiming to elevate business sophistication and expertise.

The six divisions will carry out specialized roles. The BD division will oversee differentiated business portfolios and forming international partnerships, while the Bio Research division will focus on enhancing the product portfolio.

In tandem with this organizational overhaul, a new QE unit will be established within the Quality division, previously composed of Quality Control (QC) and Quality Assurance (QA) units. The QE unit will take the lead in elevating the production processes of the Andong L House vaccine factory and the upcoming 2025 completion of the Songdo Global R&PD Center to meet the standards of good manufacturing practices (cGMP) prevalent in the United States. Kim Joon-mo, formerly with Pfizer and an expert in bio-production and quality enhancement, will assume the director role for QE.

By Kim Jee-hee and Minu Kim

List

Previous: Lotte’s Jamsil Christmas Town sees 21 percent increase in visitors

Next: IMM PE promotes Kim Eugene as its first female partner